BioLine Rx BLRX is preparing to release its quarterly earnings on Monday, 2024-11-25. Here’s a brief overview of what investors should keep in mind before the announcement.

Analysts expect BioLine Rx to report an earnings per share (EPS) of $-0.10.

Anticipation surrounds BioLine Rx’s announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.

New investors should understand that while earnings performance is important, market reactions are often driven by guidance.

Overview of Past Earnings

During the last quarter, the company reported an EPS beat by $0.14, leading to a 8.88% increase in the share price on the subsequent day.

Here’s a look at BioLine Rx’s past performance and the resulting price change:

BioLine Rx Share Price Analysis

Shares of BioLine Rx were trading at $0.32325 as of November 21. Over the last 52-week period, shares are down 77.86%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.

To track all earnings releases for BioLine Rx visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.